SCGE Phase II Planning Workshop: Expert Discussants

Carsten Bönnemann, MD

Senior Investigator, Neuromuscular and Neurogenetics Disorders of Childhood Section National Institute of Neurological Disorders and Stroke, National Institutes of Health

Murat Cirit, PhD

CEO and Co-Founder
Javelin Biotech

Philip Gregory, DPhil

Chief Scientific Officer bluebird bio

Rachel Haurwitz, PhD

President and CEO Caribou Biosciences

Patrick Hsu, PhD

Assistant Professor, Department of Bioengineering University of California Berkeley

Keith Joung, MD, PhD

Professor of Pathology

Massachusetts General Hospital & Harvard Medical School

Anna Kwilas, PhD

Gene Therapy CMC Team Lead

Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies

Tippi MacKenzie, MD

Professor of Surgery, Division of Pediatric Surgery University of California, San Francisco

Peter Marks, MD, PhD

Director

Food and Drug Administration, Center for Biologics Evaluation and Research

William H. Peranteau, MD

Assistant Professor of Surgery Children's Hospital of Philadelphia

Jordan Pober, MD, PhD

Director, Human and Translational Immunology Program Yale School of Medicine

Pablo Ross, PhD

Professor, Department of Animal Science University of California, Davis

Laura Sepp-Lorenzino, PhD

Chief Scientific Officer Intellia Therapeutics

Zuben E. Sauna, PhD

Principal Investigator, Immunogenicity of Protein-based Therapeutics, and CMC Reviewer Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies

Megan Sykes, MD

Director

Columbia Center for Translational Immunology

John Tisdale, MD

Senior Investigator and Director, Cellular and Molecular Therapeutics Branch National Heart, Lung, and Blood Institute, National Institutes of Health

Luk Vanderberghe, PhD

Associate Professor of Ophthalmology Harvard Medical School

Amy Wagers, PhD

Forst Family Professor of Stem Cell and Regenerative Biology Harvard University; Harvard Medical School

J. Fraser Wright, PhD

Professor of Pediatrics, Center for Definitive and Curative Medicine Stanford University School of Medicine

Timothy Yu, MD, PhD

Staff Physician & Research Faculty, Division of Genetics & Genomics Boston Children's Hospital Associate Professor Harvard Medical School

SCGE Phase II Planning Workshop: Session Moderators

PJ Brooks, PhD

Program Director, Office of Rare Diseases Research
National Center for Advancing Translational Sciences, National Institutes of Health

Paula Cannon, PhD

Distinguished Professor, Department of Molecular Microbiology & Immunology Keck School of Medicine, University of Southern California

Katherine High, MD

President, Therapeutics

AskBio

Professor Emerita, Perelman School of Medicine of the University of Pennsylvania

Vic Myer, PhD

Entrepreneur In Residence Atlas Venture

Marrah Lachowicz-Scroggins, PhD

Program Director, Airway Biology and Disease Branch National Heart, Lung, and Blood Institute, National Institutes of Health

Oleg Mirochnitchenko, PhD

Health Scientist Administrator, Division of Comparative Medicine
Office of Research Infrastructure Programs, Office of the Director, National Institutes of Health

Betty Poon, PhD

Program Officer, Targeted Interventions Branch National Institute of Allergy and Infectious Diseases, National Institutes of Health

Fyodor Urnov, PhD

Scientific Director of Technology and Translation Innovative Genomics Institute

Other NIH Attendees

Additional NIH leadership and program staff are expected to join in listen-only mode.